The company develops and produces technologically sophisticated drugs both for systemic support of patients and for patients in intensive care, during intensive care, with blood diseases and a number of oncological diseases.
The research center of the company is working on new technologies in the field of modernization of technological processes in the production of blood products, generation of new forms of recombinant drugs, submerged cultivation of spore and non-spore probiotic microorganisms.
The company is also developing about 30 new drugs for use in dermatology, drugs that affect the musculoskeletal system, anti-inflammatory drugs, nasal drops, monoclonal antibodies.
The company annually undergoes technical supervision for compliance with ISO 9001, 13485, 22000, 1401 series. All blood products are regularly monitored for compliance with the requirements of the European Pharmacopoeia in specialized laboratories in Germany and Portugal.
The history of the company began in the 19th century in Kiev against the background of world epidemics of diphtheria, plague, typhoid fever, dysentery and Asian cholera.
In 1895, the Infectious Diseases Society was formed. With the private funds collected from Kiev, Professor Pavlovsky was equipped to Berlin and Paris and brought the technology for the production of antidiphtheria serum.
Upon his return, he and his colleagues open a laboratory at the University of St. Vladimir.
Subsequently, scientists are allocated land on Baykova Gora for the opening of the Bacteriological Institute.
April 14, 1896 becomes the starting point of the history of biopharma - on this day the construction of the Pasteur Corps begins.
Since the end of the 1960s of the twentieth century, the separation of production from the institute began. The Bacterial Preparations Factory appears. It produces infusion solutions and hormones, and in 1983 for the first time produced "Human leukocyte interferon" against the influenza virus.
In 1986, biopharma was the first in the world to release the innovative drug "Ceruloplasmin". It has a positive effect on oxygen homeostasis and immune status under the influence of ionizing radiation, toxic substances, tumor growth and influenza infection.
In 2010, the company modernized the drug production lines. biopharma receives GMP and ISO 1400: 2006 certifications, the company's production processes comply with the requirements of the environmental management system and the level of the enterprise's environmental impact.
Another key event took place in 2014 - the opening of the first stage of the biopharmaceutical research and production complex in Bila Tserkva.
biopharma today has more than 300 professionals, researchers and scientists. The company has been operating for over 120 years and exports drugs to more than 36 countries around the world.